The drug was introduced into the clinic in the 1970s for the prevention and treatment of diabetic retinopathy, and was marketed in China in June 2001. This drug mainly reduces capillary permeability, inhibits platelet aggregation reaction and reduces blood viscosity. In recent years, it has been found to improve renal function and reduce proteinuria, which has been reported in several articles, and its clinical application in chronic renal failure has been doubly respected. In the past 3 years, I have also applied calcium hydroxybenzenesulfonate in the diagnosis and treatment of patients with chronic renal failure, and indeed found that its effect of lowering creatinine in the short term was obvious, with its effect more obvious within 2 weeks, but with the extension of treatment time, creatinine and urea rose again quickly, even worse than the renal function before treatment. After noticing this problem, I started to observe patients taking calcium hydroxybenzene sulfonate 1 year ago, and have observed more than 10 cases since then, testing renal function, urinary routine, etc., and performing ECT to check glomerular filtration rate (GFR) before, 2 weeks, and 12 weeks of calcium hydroxybenzene sulfonate, respectively. The monitoring results suggested that there was no significant change in urine protein, creatinine first decreased and then gradually increased, no significant change in glomerular rate filtration, and gradual increase in cystine protease inhibitor C. Based on the above results, I initially judged that calcium hydroxybenzenesulfonate had no significant benefit on the improvement of renal function, the reason of which is yet to be further explored. I personally believe that patients with renal failure, especially those with non-diabetic nephropathy, should not take calcium hydroxybenzenesulfonate to avoid interfering with the monitoring of patients’ conditions and affecting their treatment.